Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12536905 | 0.87 | TACR3 (0.39) | KMT2AMEN1SMN1; SMN2CHRM4 | |
| SCHEMBL4242136 | 0.87 | LMNA (0.47) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL2307070 | 0.84 | KMT2A (0.55) | KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL1920545 | 0.82 | HRH3 (0.35) | GRM4 | |
| SCHEMBL733745 | 0.82 | HRH3 (0.35) | GRM4 | |
| SCHEMBL733358 | 0.82 | HRH3 (0.35) | GRM4 | |
| SCHEMBL14700307 | 0.82 | HRH3 (0.35) | GRM4 | |
| SCHEMBL1947120 | 0.81 | RXFP1 (0.40) | KMT2AMEN1SMN1; SMN2LMNA | |
| SCHEMBL15039462 | 0.79 | GRM4 (0.33) | GRM4 | |
| SCHEMBL13493085 | 0.77 | SLC6A2 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1989196-B1 | PIPERIDINOYLPYRROLIDINES AS MELANOCORTIN TYPE 4 RECEPTOR AGONISTS | PFIZER LTD (GB) | 2013-02-13 | — | — | EP | disclosed |
| US-8138188-B2 | Melanocortin type 4 receptor agonist piperidinoylpyrrolidines | PFIZER INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138188-B2 | Melanocortin type 4 receptor agonist piperidinoylpyrrolidines | PFIZER INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138188-B2 | Melanocortin type 4 receptor agonist piperidinoylpyrrolidines | PFIZER INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090036459-A1 | Melanocortin Type 4 Receptor Agonist Piperidinoylpyrrolidines | PFIZER INC | 2009-02-05 | — | — | US | disclosed |
| US-20090036459-A1 | Melanocortin Type 4 Receptor Agonist Piperidinoylpyrrolidines | PFIZER INC | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036459-A1 | Melanocortin Type 4 Receptor Agonist Piperidinoylpyrrolidines | MC4R, MC5R, MC3R | KMT2A 2041/4885MEN1 798/4885SMN1; SMN2 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.